Best Infectious Diseases Companies in Israel
The 46 best Infectious Diseases companies in Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: MeMed.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Israel
| # | Company | Disclosed funding | Last round | Founder | Employees | Stage | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | 101 Therapeutics Developer of therapeutics for infectious diseases | — | — | James Goldberg Co-Founder | 2 | Funding Raised | — | 7 patents Antiviral pharmaceutical compositions and treatment methods for SARS‑CoV‑2 infections | — |
| 2 | 3Biotix Developer of therapeutics for infectious diseases | — | — | Alon Barzilay Co-Founder | — | Deadpooled | — | — | — |
| 3 | 3qbd POC molecular diagnostic device for vaginal infections | — | — | Moshe Golan President & CEO | 5 | Deadpooled | — | — | — |
| 4 | BactoByte Developer of invitro bactial diagnostic method and antibiotic screening | — | — | Miron Krokhmal CEO | 9 | Funding Raised | — | 6 patents Rapid microbial detection diagnostics and assay technologies | — |
| 5 | Diagnoz.me Developer of system for diagnostic microscopy | — | — | Ariel Livne Co-Founder & CEO | — | Unfunded | — | — | — |
| 6 | EDAS Healthcare Provider of diagnostic system for infectious disease | — | — | Guy Livne Co-Founder & CEO | — | Funding Raised | — | — | — |
| 7 | Eve Pharma Drug delivery product for the treatment of bacterial vaginosis | — | — | Eran Eilat Founder | — | Deadpooled | — | — | — |
| 8 | Hylabs Manufacturer and distributor of tools for pathogen detection | — | — | — | 47 | Unfunded | WordPressPleskMySQL+33 | — | — |
Top 12 Infectious Diseases companies in Israel
#1
Series C · Jerusalem, Jerusalem District · founded 2015 · 17 employees$24.3Mraised▾
Developer of antimicrobial peptides for the treatment of drug-resistant bacterial infections. The lead candidate OMN6 targets gram-negative bacteria. Other candidates include OMN-XF for multi-drug resistance fungi and OMN-XGP for gram-positive bacteria. The technology is based on natural antimicrobial peptides which are genetically engineered for stability and for proteolytic degradation pruning.
- Oct 2025Series C$25M
- Oct 2023Grant (prize money)$52.9K
- Aug 2021Grant (prize money)—
- Jul 2021Grant (prize money)$2.8M
#2
Series D · Tirat Carmel, Haifa District · founded 2009 · 121 employees$163Mraised▾
MeMed Diagnostics provides machine learning-based diagnostic solutions for infectious diseases. The company's lead product ImmunoXpert, distinguishes between bacterial and viral infections based on the patient’s immune response in-vitro diagnostic test. The company also offers ImmunoPoC, a device for distinguishing between bacterial and viral infections at the point-of-care. The company also provides its immunoassay platform MeMed Key. Its solution also diagnoses infections inaccessible for direct pathogen sampling and avoids false alarms due to the presence of non-pathogenic bacteria and viruses.
- Jan 2022Series D$93M
- Jan 2020Grant (prize money)$2.8M
- Nov 2019Grant (prize money)$2.8M
- Nov 2018Grant (prize money)$3.3M
#3
Public · Ramat Gan, Tel Aviv District · founded 2009 · 183 employees$13.5Mraised▾
Developer of therapeutics for the treatment of gastrointestinal and infectious diseases. The company is focusing on the development of proprietary, orally-administered, small molecule drugs for the treatment of multiple diseases. The company’s product pipeline includes RHB-204, RHB-104, RHB-102, and RHB-106 for H. pylori infections, Crohn's disease, Gastroenteritis gastritis, solid tumor, pancreatic cancer, Migraine, and other diseases.
- Jan 2024Post IPO$10M
- Oct 2023Post IPO$4M
- Aug 2023Post IPO$2.7M
- Sep 2020Grant (prize money)$300K
#4
Series B · Rehovot, Central District · founded 2017 · 15 employees$20Mraised▾
Developer of microbiome-based therapeutics to treat immune-mediated and infectious diseases. The company uses PRISM a proprietary computational analysis and predictive capabilities to identify BMC128 a combinational therapy for Non-small-cell lung carcinoma. Also, it develops drug candidates for multi drug-resistant organisms and gastrointestinal diseases.
- Apr 2023Series B$20M
#5
Public · Ness Ziona, Center District · founded 2003$49.9Mraised▾
Developer of a vaccine against influenza virus. Its lead candidate M-001, a nanosized antibody vaccine to protect against seasonal and pandemic influenza. Its technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate both arms of the immune system for a cross-protecting and long-lasting effect.
- Apr 2019Conventional Debt$26.9M
- Oct 2018Conventional Debt$9.2M
- Aug 2018Conventional Debt$6.8M
- Jun 2018Conventional Debt$7M
#6
Series A · Yokneam Illit, Northern District · founded 2016 · 12 employees$900Kraised▾
Provider of point of care diagnostic device. It offers a hand held programmable diagnostic device RevDx system which is used for automatic hematology tests and infectious disease diagnostics. The system is an AI based platform that combines optomechanics, electrochemistry, and bioengineering technologies. It aims to provide its device in the primary care setting, home hospitalization, and remote locations where proper disease diagnosis is required.
- Apr 2024Series A$6.5M
- Dec 2018Seed$900K
#7
Acqui-Hired · Rehovot, Central District · founded 2005$53.8Mraised▾
SciVac Therapeutics (formerly SciGen IL) was a clinical stage company focussed on developing a vaccine for viral infections. It had developed hepatitis B (HBV) vaccine that mimics all three viral surface antigens of the hepatitis B virus which provides rapid onset of protection, high levels of anti-HBV antibodies, and can be administered at lower doses than competing HBV vaccines. The vaccine was approved in Israel and in 14 other countries . In May 2016, SciVac Therapeutics merged with VBI Vaccines and changed its name to VBI Vaccines. It's Israel unit is currently serving as contract development unit.
- Jul 2015Post IPO—
- Oct 2014Post IPO$4.4M
- Aug 2010Post IPO$274.7K
#8
Seed · Rehovot, Central District · founded 2014 · 27 employees$4.7Mraised▾
Developer of microbiome-based therapeutics to treat various diseases. The company's product pipeline for cancer vaginal dysbiosis and the gastrointestinal solution is under the preclinical phase. It uses fermentation and formulation technology for the development of therapeutics. The company's technology platform includes MyCrobe (Single strain fermentation and formulation technology), SuperDonor (microbiome production and recovery technology), SuperDonor Select (Next-generation multi-strain technology), and MyLiveIn (AI-enabled design platform)
- May 2022Grant (prize money)$53.8K
- Feb 2021Seed—
- Oct 2020Grant (prize money)$2.4M
- Jun 2020Grant (prize money)$2.2M
#9
Funding Raised · Haifa, Haifa District · founded 2007$2.7Mraised▾
Developer of bio-electronic molecular diagnostic device for rapid medical testing. The company offers "Miniature Enthalpy-Meter" for the rapid and accurate diagnosis of pathogens such as antibiotic resistant bacteria, pandemic viruses and bio-terror agents.
- Dec 2021Grant (prize money)$56.6K
- Jul 2019Grant (prize money)$2.6M
#10
Funding Raised · Ashkelon, South District · founded 2011 · 6 employees$2.2Mraised▾
Provider of quantum optics analyzers for molecular level diagnostics. Its technology uses a general-purpose stimulated Raman Scattering spectrophotometric module that enables the development of a complete Raman spectrum for multiple molecules at once. Its device is an ICU bedside monitor that detects the presence of ventilator-associated pneumonia before the onset of symptoms. In addition, it has products for production control, energy, and environmental applications.
- Oct 2021Grant (prize money)$57.8K
- May 2019Grant (prize money)$2M
- Apr 2018Grant (prize money)$60.6K
- Jan 2018Grant (prize money)$60.1K
#11
Acquired · Tel Aviv, Tel Aviv · founded 2017 · 17 employees$3.1Mraised▾
Developer of a rapid diagnostic test for bacterial infections. The company has developed a diagnostic test that checks bacterial resistance to antibiotics using microfluidics techniques. It provides results by fluorescence analysis that indicates the level of metabolic activity and helps doctors determine the appropriate antibiotic treatment for their patients.
- Oct 2020Grant (prize money)$3M
- Jun 2018Grant (prize money)$58.3K
- 2017Grant (prize money)—
#12
Funding Raised · Nesher, Haifa District · founded 2016 · 18 employees$2.1Mraised▾
Sanolla has developed diagnostics systems to detect multiple diseases such as COVID-19, cardiovascular and pulmonary diseases. The company has developed propriety AI-powered infrasound analysis technology with an integrated disease classifier that is used for self-assessment and analysis of the body’s full spectrum of sounds. The frequency shifting algorithms convert the infrasound into the audible range and analyse the sound spectrum in a proprietary sound signature to detect various health conditions.
- Dec 2020Grant (prize money)$2.1M
- Sep 2020Grant (prize money)—
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Diagnostics is moving in Israel
A read on the academic research around Diagnostics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 169 Israel-affiliated papers.
- Tel Aviv University24
- Ben-Gurion University of the Negev23
- Hebrew University of Jerusalem22
- Hadassah Medical Center21
- Technion – Israel Institute of Technology18
- Liquid biopsy1→15
- Cancer1→7
- Point-of-care testing2→5
- Liquid biopsy2→26
- Internal medicine1→5
- Oncology1→4
- Point-of-care testing2→6
Where diagnostics is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.